You Will Encounter HPS In:

1. Simultaneous liver-kidney transplantation (SLKT) evaluation — HPS may affect transplant candidacy
2. Dialysis patient with cirrhosis — HPS worsens hypoxemia during volume shifts; need specialized management
3. Perioperative management — Liver transplant recipients with acute kidney injury; HPS complicates anesthesia
4. Multidisciplinary cirrhosis care — Hepatorenal syndrome + HPS create complex management challenges

Prevalence

• 5-32% of liver transplant candidates (varies by diagnostic criteria used)
• More common than initially appreciated
• Often undiagnosed until late stages
• Present in ~13% of patients with cirrhosis

1. Liver Disease (Portal Hypertension ± Cirrhosis)

• Any stage of liver disease with portal hypertension
• Can occur with or without cirrhosis
• Examples: Cirrhosis (any etiology), portal vein thrombosis, non-cirrhotic portal hypertension

2. Intrapulmonary Vascular Dilatations (IPVDs)

• Abnormal dilation of pulmonary precapillary and capillary vessels
• Normal vessel diameter: 8-15 μm
• In HPS: 15-500 μm (grossly dilated)
• Confirmed by:
  • Contrast-enhanced transthoracic echocardiography (CE-TTE) — gold standard, >95% sensitivity
  • 99mTc-MAA (technetium-99m macroaggregated albumin) lung perfusion scan — measures shunt fraction

3. Impaired Oxygenation (At Rest, Room Air)

• Partial pressure of oxygen (PaO2) <80 mmHg on room air at sea level, OR
• Alveolar-arterial oxygen gradient (A-a gradient) ≥15 mmHg (≥20 mmHg if age >64)

Clinical Pearl: Do NOT rely on SpO2 alone! Pulse oximetry can be falsely reassuring. You MUST check arterial blood gas (ABG) to diagnose HPS.

Clinical Tip

Very severe HPS (PaO2 <50) may actually contraindicate complex transplantation like SLKT. The perioperative mortality risk can exceed 30%. Isolated liver transplantation is safer but still risky.

The Three Mechanisms of Oxygen Impairment

Molecular Mechanisms Driving IPVD Formation

The liver overproduces:

Net Result: Progressive, diffuse pulmonary vascular dilatation.

Orthodeoxia

Definition: Hypoxemia that worsens in the upright position and improves when supine (lying flat).

Mechanism: - IPVDs concentrate in lung bases - Upright position → Gravity increases perfusion to bases → More blood flows through dilated vessels → Greater shunting → Worse O2 uptake - Supine position → Gravity redistributes perfusion more evenly → Less preferential flow through basal dilated vessels → Better oxygenation

Clinical Example: - Seated SpO2 = 88% and dyspneic - Lying supine SpO2 = 94% and breathing easier

Platypnea

Definition: Dyspnea that worsens in upright position and improves when lying down.

This is orthodeoxia’s clinical companion — the symptom that goes with the oxygenation worsening.

Why This Matters

• If you see orthodeoxia + platypnea in a cirrhotic patient with hypoxemia, think HPS immediately
• This is highly specific for HPS (not seen in typical pulmonary hypertension, ILD, or ARDS)
• Ask patients: “Does your breathing feel worse when you sit up?” If yes, check ABG with patient supine vs. sitting

Step 1: Suspect HPS in a Cirrhotic Patient With Hypoxemia

You should obtain arterial blood gas (ABG) and measure A-a gradient in any patient with: - Cirrhosis + dyspnea - Portal hypertension + abnormal saturation - Hypoxemia that seems out of proportion to lung findings on exam/X-ray - Positional dyspnea (worse upright, better supine)

Step 2: Confirm Oxygenation Impairment

Arterial Blood Gas (ABG): - Measure PaO2 and calculate A-a gradient = (PAO2 - PaO2) - PAO2 = (FiO2 × [Pbaro - PH2O]) - (PaCO2 / RQ) - At sea level, room air: PAO2 ≈ 150 - (PaCO2/0.8) - HPS diagnosed if: PaO2 <80 mmHg OR A-a ≥15 (≥20 if age >64)

Step 3: Detect Intrapulmonary Vascular Dilatations

Step 4: Classify by Severity

Once HPS is confirmed, use PaO2 or A-a gradient to assign grade (mild/moderate/severe/very severe).

Symptoms

Physical Examination

Laboratory/Imaging

• ABG: PaO2 <80, elevated A-a gradient
• CXR: Usually normal or near-normal — this is a vascular disease, not parenchymal
• Pulmonary Function Tests: Reduced DLCO (diffusing capacity), normal FEV1/FVC
• Echo: RV dilatation possible; RV systolic pressure normal to mildly elevated (unlike pulmonary arterial hypertension)

The Fundamental Reality

Liver transplantation is the ONLY definitive treatment for HPS. - PaO2 improvement occurs in 80-85% of transplant recipients within 6-12 months - No pharmacologic agent has proven consistently effective

What Doesn’t Work (Important to Know)

Despite trials, these agents have NOT shown sustained benefit: - Inhaled nitric oxide - Methylene blue - Garlic - Pentoxifylline - Somatostatin - Mycophenolate

Teaching Point: Don’t waste time on these. Transplant evaluation is the priority.

Why HPS Gets MELD Exception Points

The MELD score (Model for End-Stage Liver Disease) predicts transplant urgency based on bilirubin, INR, and creatinine. But HPS patients can have normal synthetic function and low MELD scores yet face high mortality from hypoxemia alone.

Therefore: HPS is an independent indication for MELD exception points if: - PaO2 <60 mmHg on room air at sea level - Documented intrapulmonary vascular dilatations - Evaluation for liver transplantation underway

This gives HPS patients priority on transplant waiting lists because their hypoxemia, not their liver biochemistry, drives mortality.

Perioperative Management (Bridge to Transplant)

While waiting for transplant, manage HPS supportively:

1. Dialysis Management Becomes Challenging

• Volume shifts during HD can worsen V/Q mismatch → acute hypoxemia
• Patient already hypoxic at baseline; dialysis can tip them into crisis
• Solution: Consider continuous modalities (CRRT, peritoneal dialysis) for more gradual solute/fluid removal

2. Transplant Candidacy Worsens

• Very severe HPS (PaO2 <50) + HRS = very high perioperative risk
• Simultaneous liver-kidney transplantation (SLKT) may be too risky
• Single-organ liver transplant alone may be preferred
• Kidney function usually recovers post-liver transplant if HRS was the cause

3. Anesthesia Risk is Increased

• Intubation increases hypoxemia risk
• Prone positioning (some surgeries) worsens orthodeoxia
• Careful anesthesia planning with pulmonology input is essential

Question 1: Case Presentation

A 62-year-old woman with cirrhosis (Child-Pugh B) presents with progressive dyspnea over 6 months. She reports her shortness of breath is much worse when sitting up but improves dramatically when she lies down. Physical exam shows ascites and spider telangiectasias but clear lungs. CXR is normal. Resting SpO2 = 92%.

Which test should you order next to evaluate for HPS?

A. Pulmonary function testing (PFTs) B. Arterial blood gas (ABG) with patient both seated and supine C. High-resolution CT chest D. Right heart catheterization

Answer: B. This patient has classic orthodeoxia and platypnea (dyspnea worse upright, better supine). You must confirm the oxygenation impairment with ABG and calculate the A-a gradient. The positional nature strongly suggests HPS. ABG is the first confirmatory step. (PFTs come later; HRCT not needed; RHC would show normal pressures in HPS, not the elevated pressures of PAH.)

Question 2: Mechanism Question

A patient with HPS and PaO2 = 58 mmHg is given supplemental oxygen (FiO2 100% by non-rebreather). His PaO2 improves to 62 mmHg. This minimal response to high-concentration oxygen is best explained by:

A. Hypoventilation from encephalopathy B. Intrapulmonary right-to-left shunting through dilated vessels — oxygen can’t reach the shunted blood C. Pulmonary fibrosis preventing oxygen diffusion D. Anemia reducing oxygen-carrying capacity

Answer: B. This is the key principle of HPS: A true right-to-left shunt (blood bypassing ventilated alveoli) does NOT respond well to supplemental oxygen because the shunted blood is never exposed to high-oxygen air. In contrast, V/Q mismatch or hypoventilation improves with supplemental O2. The relative lack of response to high FiO2 is actually diagnostic of a significant shunt, which is characteristic of HPS.

Question 3: Management Question

A 55-year-old man with cirrhosis is found to have HPS with PaO2 = 68 mmHg and documented IPVDs on CE-TTE. He is not a transplant candidate due to advanced hepatocellular carcinoma (HCC) beyond transplant criteria. He remains short of breath despite supplemental oxygen.

What is the most appropriate next step?

A. Start inhaled nitric oxide therapy B. Start a pulmonary vasodilator (sildenafil) C. Refer to palliative care; optimize comfort; discuss prognosis D. Start albumin dialysis (MARS system)

Answer: C. This is a prognostically difficult situation. Without transplant as an option, pharmacologic therapies for HPS lack strong evidence and don’t alter the trajectory. The compassionate approach is palliative care focus: optimize symptom control (oxygen), discuss realistic prognosis (HPS without transplant carries high mortality), and ensure the patient’s values/wishes are understood. (Nitric oxide and sildenafil lack robust data; MARS is investigational.)